The increase was driven by higher selling and marketing and G&A expenses offset by a decrease in R&D. R&D expenses decreased by 26% to 1.7 million, driven by the approval of DefenCath. CorMedix is now reporting selling and marketing expense and general and administrative expense as separate line items. On an apples-to-apples basis, S&M expense increased 1% to 8.3 million in the fourth quarter of 2024 compared with 8.2 million in the fourth quarter of '23.